Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Apple Inc (AAPL) vs Abeona Therapeutics Inc (ABEO) Price & Performance

Abeona Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Apple Inc vs Abeona Therapeutics Inc — how do they compare? Apple Inc trades at $304.75 (market cap $4.45T), while Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M). The key difference: Apple Inc is far larger — about 10565.3× Abeona Therapeutics Inc's market cap, and Apple Inc pays a 0.35% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

AAPLABEO
Market Cap
$4.45T$421.19M
Volume
100,358,844
Sector
TechnologyHealth
52-Week High
$340.08$7.45
52-Week Low
$224.90$4.17
Enterprise Value
$4.47T$276.10M
Dividend Yield
0.35%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Apple Inc

AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal and support near $306. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.98. Revenue grew to $416.16B in 2025, and net income margin improved to 27.62%. Recent news highlights AI potential through a partnership with Alphabet's Gemini, but store closures and union disputes pose headwinds.

Outlook remains positive with a consensus price target of $337.63, implying 9.5% upside, supported by robust cash flow and a 63.6% buy rating from analysts. Risks include weaker iPhone sales, regulatory fines, and competitive pressures in AI. The stock offers growth potential but requires monitoring of execution risks and macroeconomic trends.

Abeona Therapeutics Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Apple Inc

Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.

Read more on AAPL

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO